The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1303-1310

  Van Der Pas, R ^a   De Bruin, C ^a   Leebeek, F W G ^a   De Maat, M P M ^a   Rijken, D C ^a   Pereira, A M ^b   Romijn, J A ^b   Netea Maier, R T ^c   Hermus, A R ^c   Zelissen, P M J ^d   De Jong, F H ^a   Van Der Lely, A J ^a   De Herder, W W ^a   Lamberts, S W J ^a   Hofland, L J ^a   Feelders, R A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ALPHA 2 ANTIPLASMIN; ANTICOAGULANT AGENT; ANTIGEN; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CABERGOLINE; CORTICOSTEROID; FIBRINOGEN; KETOCONAZOLE; LOW MOLECULAR WEIGHT HEPARIN; PASIREOTIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROCOAGULANT; PROTEIN C; PROTEIN S; PROTHROMBIN; SOMATOSTATIN DERIVATIVE; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CUSHING DISEASE; DRUG DOSE INCREASE; FEMALE; FIBRINOGEN BLOOD LEVEL; FIBRINOLYSIS; HEMOSTASIS; HORMONE URINE LEVEL; HUMAN; HYPERCOAGULABILITY; LOW DRUG DOSE; LUNG EMBOLISM; MALE; MONOTHERAPY; NETHERLANDS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECURRENT DISEASE; REMISSION; TREATMENT RESPONSE;

ADULT; AGED; BLOOD COAGULATION; BLOOD COAGULATION FACTORS; DOPAMINE AGONISTS; DRUG MONITORING; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; ERGOLINES; FIBRINOLYSIS; HUMANS; HYDROCORTISONE; KETOCONAZOLE; MALE; MIDDLE AGED; PITUITARY ACTH HYPERSECRETION; PITUITARY HORMONES, ANTERIOR; REMISSION INDUCTION; SOMATOSTATIN; THROMBOPHILIA; YOUNG ADULT;

EID: 84859541722     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2753     Document Type: Article

References (40)

1. Newell-Price J, Bertagna X, Grossman AB, Nieman LK 2006 Cushing's syndrome. Lancet 367:1605-1617 (Pubitemid 43674231)
2. Van Zaane B, Nur E, Squizzato A, Dekkers OM, Twickler MT, Fliers E, Gerdes VE, Büller HR, Brandjes DP 2009 Hypercoagulable state in Cushing's syndrome: a systematic review. J Clin Endocrinol Metab 94:2743-2750
3. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M 2003 Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602 (Pubitemid 38033020)
4. Stuijver DJ, van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, van den Berg G, Pereira AM, de Herder WW, Wagenmakers MA, Kerstens MN, Zelissen PM, Fliers E, Schaper N, Drent ML, Dekkers OM, Gerdes VE 2011 Incidence of venous thromboembolism in patients with Cushing's syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525-3532
5. Blichert-Toft M, Bagerskov A, Lockwood K, Hasner E 1972 Operative treatment, surgical approach, and related complications in 195 operations upon the adrenal glands. Surg Gynecol Obstet 135:261-266
6. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A 2002 Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's syndrome. J Clin Endocrinol Metab 87:3662-3666 (Pubitemid 34879509)
7. Pezzulich RA, Mannix Jr H 1970 Immediate complications of adrenal surgery. Ann Surg 172:125-130
8. Sjöberg HE, Blombäck M, Granberg PO 1976 Thromboembolic complications, heparin treatment in increase in coagulation factors in Cushing's syndrome. Acta Med Scand 199:95-98
9. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavagnini F, Mannucci PM 2000 Markers of activation of coagulation and fibrinolysis in patients with Cushing's syndrome. J Endocrinol Invest 23:145-150 (Pubitemid 30218782)
10. Patrassi GM, Sartori MT, Viero ML, Scarano L, Boscaro M, Girolami A 1992 The fibrinolytic potential in patients with Cushing's disease: a clue to their hypercoagulable state. Blood Coagul Fibrinolysis 3:789-793 (Pubitemid 23026824)
11. Ambrosi B, Sartorio A, Pizzocaro A, Passini E, Bottasso B, Federici A 2000 Evaluation of haemostatic and fibrinolytic markers in patients with Cushing's syndrome and in patients with adrenal incidentaloma. Exp Clin Endocrinol Diabetes 108:294-298 (Pubitemid 30458601)
12. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A 1999 Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing's syndrome. Blood Coagul Fibrinolysis 10:145-151 (Pubitemid 29225577)
13. Dal Bo Zanon R, Fornasiero L, Boscaro M, Ruffato G, Luzzato G, Fabris F, Girolami A 1983 Clotting changes in Cushing's syndrome: elevated factor VIII activity. Folia Haematol Int Mag Klin Morphol Blutforsch 110:268-277
14. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H 2009 Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 32:169-174
15. Feldman BF, Rasedee A, Feldman EC 1986 Haemostatic abnormalities in canine Cushing's syndrome. Res Vet Sci 41:228-230
16. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Aganovic I, Korsic M 2009 Hypercoagulability in Cushing's syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36:70-74
17. Lippi G, Franchini M, Salvagno GL, Montagnana M, Guidi GC 2008 Higher morning serum cortisol level predicts increased fibrinogen but not shortened APTT. J Thromb Thrombolysis 26:103-105
18. Terzolo M, Allasino B, Bosio S, Brusa E, Daffara F, Ventura M, Aroasio E, Sacchetto G, Reimondo G, Angeli A, Camaschella C 2004 Hyperhomocysteinemia in patients with Cushing's syndrome. J Clin Endocrinol Metab 89:3745-3751 (Pubitemid 39071467)
19. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E 2010 Changes of coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's syndrome: results from a prospective study before and after surgery. Eur J Endocrinol 163:783-791
20. Kelly DF 2007 Transsphenoidal surgery for Cushing's disease: a review of success rates, remission predictors, management of failed surgery, and Nelson's syndrome. Neurosurg Focus 23:E5
21. Lamberts SW, van der Lely AJ, de Herder WW 1995 Transsphenoidal selective adenomectomy is the treatment of choice in patients with Cushing's disease. Considerations concerning preoperative medical treatment and the long-term follow-up. J Clin Endocrinol Metab 80:3111-3113
22. Estrada J, Boronat M, Mielgo M, Magallón R, Millan I, Díez S, Lucas T, Barceló B 1997 The long-term outcome of pituitary irradiation after unsuccessful transsphenoidal surgery in Cushing's disease. N Engl J Med 336:172-177 (Pubitemid 27034962)
23. de Bruin C, Pereira AM, Feelders RA, Romijn JA, Roelfsema F, Sprij-Mooij DM, van Aken MO, van der Lelij AJ, de Herder WW, Lamberts SW, Hofland LJ 2009 Coexpression of dopamine and somatostatin receptor subtypes in corticotroph adenomas. J Clin Endocrinol Metab 94:1118-1124
24. Hofland LJ, van der Hoek J, Feelders R, van Aken MO, van Koetsveld PM, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, de Herder WW, Beckers A, Lamberts SW 2005 The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured humancorticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol 152:645-654 (Pubitemid 40575811)
25. Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, Annunziato L, Lombardi G, Colao A, Hofland LJ, Lamberts SW 2004 Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab 89:2452-2462 (Pubitemid 38619889)
26. Feelders RA, de Bruin C, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PM, van Heerebeek R, de Jong FH, van der Lely AJ, de Herder WW, Hofland LJ, Lamberts SW 2010 Pasireotide alone or with cabergoline and ketoconazole in Cushing's disease. N Engl J Med 362:1846-1848
27. de Bos Kuil MJ, Endert E, Fliers E, Prummel MF, Romijn JA, Wiersinga WM 1998 Establishment of reference values for endocrine tests. I: Cushing's syndrome. Neth J Med 53:153-163 (Pubitemid 28464609)
28. Clauss A 1957 [Rapid physiological coagulation method in determination of fibrinogen]. Acta Haematologica 17:237-246
29. Hoekstra J, Guimarães AH, Leebeek FW, Darwish Murad S, Malfliet JJ, Plessier A, Hernandez-Guerra M, Langlet P, Elias E, Trebicka J, Primignani M, Garcia-Pagan JC, Valla DC, Rijken DC, Janssen HL 2010 Impaired fibrinolysis as a risk factor for Budd-Chiari syndrome. Blood 115:388-395
30. Brotman DJ, Girod JP, Posch A, Jani JT, Patel JV, Gupta M, Lip GY, Reddy S, Kickler TS 2006 Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res 118:247-252 (Pubitemid 43833323)
31. Leebeek FW, Goor MP, Guimaraes AH, Brouwers GJ, Maat MP, Dippel DW, Rijken DC 2005 High functional levels of thrombinactivatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 3:2211-2218 (Pubitemid 41727199)
32. Hamsten A, Wiman B, de Faire U, Blombäck M 1985 Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl JMed 313:1557-1563 (Pubitemid 16177394)
33. Guimarães AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FW 2009 Hypofibrinolysis isarisk factor for arterial thrombosis at young age. Br J Haematol 145:115-120
34. Lisman T, de Groot PG, Meijers JC, Rosendaal FR 2005 Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 105:1102-1105 (Pubitemid 40170881)
35. Mertens I, Van Gaal LF 2002 Obesity, haemostasis and the fibrinolytic system. Obes Rev 3:85-101 (Pubitemid 34827150)
36. Targher G, Zoppini G, Moghetti P, Day CP 2010 Disorders of coagulation and hemostasis in abdominal obesity: emerging role of fatty liver. Semin Thromb Hemost 36:41-48
37. Stein PD, Beemath A, Olson RE 2005 Obesity as a risk factor in venous thromboembolism. Am J Med 118:978-980 (Pubitemid 41297761)
38. Boden G, Vaidyula V, Homko C, Mozzoli M, Rao AK 2007 Differential effects of somatostatin on circulating tissue factor procoagulant activity and protein. Am J Physiol Endocrinol Metab 292:E1333-E1339 (Pubitemid 46684602)
39. Negrev N, Nyagolov Y, Stanchewa E 1995 Somatotropin and somatostatin effects on vitamin K-dependent plasma coagulation factors. Eur J Pharmacol 277:145-149
40. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A 2008 A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111:3540-3545